Boston Scientific reports Q2 2026 net sales $5.442 billion
GAAP net income rose to $907 million, adjusted EPS $0.86 beat guidance, and full-year organic growth guided at 5-6%.
See the latest news and media coverage for Boston Scientific. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global medical device manufacturer
bostonscientific.comLast updated
In short: Boston Scientific faced a global restructuring plan and guidance cuts due to a slowdown in key heart device sales and product recalls.
GAAP net income rose to $907 million, adjusted EPS $0.86 beat guidance, and full-year organic growth guided at 5-6%.
The eCoin System is a tibial nerve stimulator for urge urinary incontinence.
The SEISMIQ 4CE catheter met primary safety and effectiveness endpoints for treating severe coronary artery disease.
The ASR with JPMorgan will repurchase 80% of the $2 billion upfront, settled by June 2026, accretive to EPS.
Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” s...
On August 12, 2026, we delve into the DCF analysis for Boston Scientific Corp (BSX), a company that has seen significant fluctuations in its stock...
Boston Scientific (NYSE: BSX) has initiated multiple product recalls covering cardiac ablation...
Boston Scientific has confirmed that its Costa Rican operation forms part of a global restructuring program that sets aside as much as $300 million for...
Track Boston Scientific and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Boston Scientific and other trending companies.